[go: up one dir, main page]

MX2017008660A - Polipeptidos enlazados a il-17a. - Google Patents

Polipeptidos enlazados a il-17a.

Info

Publication number
MX2017008660A
MX2017008660A MX2017008660A MX2017008660A MX2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A MX 2017008660 A MX2017008660 A MX 2017008660A
Authority
MX
Mexico
Prior art keywords
binding polypeptides
interleukin
linked polypeptide
x26lx28x29
prognostic
Prior art date
Application number
MX2017008660A
Other languages
English (en)
Other versions
MX394167B (es
Inventor
Feldwisch Joachim
Frejd Fredrik
GUDMUNDSDOTTER Lindvi
Klint Susanne
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2017008660A publication Critical patent/MX2017008660A/es
Publication of MX394167B publication Critical patent/MX394167B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente descripción se refiere a una clase de polipéptidos preparados por ingeniería que tiene una afinidad de enlace para interleucina-17A (IL-17A), y proporciona un polipéptido enlazado a IL-17A que comprende la secuencia EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. También se describe el uso de tal polipéptido enlazado a interleucina- 17A corno un agente de diagnóstico, pronóstico y/o terapéutico.
MX2017008660A 2015-01-12 2016-01-12 Polipeptidos enlazados a il-17a. MX394167B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15150786 2015-01-12
PCT/EP2016/050456 WO2016113246A1 (en) 2015-01-12 2016-01-12 Il-17a-binding polypeptides

Publications (2)

Publication Number Publication Date
MX2017008660A true MX2017008660A (es) 2017-11-17
MX394167B MX394167B (es) 2025-03-24

Family

ID=52339024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008660A MX394167B (es) 2015-01-12 2016-01-12 Polipeptidos enlazados a il-17a.

Country Status (19)

Country Link
US (3) US10934335B2 (es)
EP (3) EP4643955A3 (es)
JP (3) JP6943764B2 (es)
KR (2) KR20240110106A (es)
CN (1) CN108064235A (es)
AU (1) AU2016208161B2 (es)
CA (1) CA2972683A1 (es)
DK (1) DK3245224T3 (es)
ES (1) ES2822431T3 (es)
HU (1) HUE052121T2 (es)
IL (1) IL253004B (es)
MX (1) MX394167B (es)
MY (1) MY188784A (es)
NZ (1) NZ732978A (es)
PL (1) PL3245224T3 (es)
PT (1) PT3245224T (es)
RU (1) RU2749712C2 (es)
WO (1) WO2016113246A1 (es)
ZA (1) ZA201704366B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN108949789A (zh) * 2018-06-26 2018-12-07 山东兴瑞生物科技有限公司 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用
MA54857A (fr) * 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN111856029B (zh) * 2020-06-19 2023-09-26 北华大学 Il-17a蛋白在膀胱癌中的应用
AU2023218534A1 (en) * 2022-02-08 2024-07-11 Affibody Ab Protein z variants binding thymic stromal lymphopoietin and their medical use
EP4504234A4 (en) 2022-04-07 2025-11-19 Acelyrin Inc TREATMENT METHODS FOR ANKYLOSING SPONDYLITIS
EP4504235A4 (en) * 2022-04-07 2025-11-19 Acelyrin Inc TREATMENT METHODS FOR HIDRADENITIS SUPPURATIVE
CN121038816A (zh) * 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用
WO2025054498A1 (en) * 2023-09-08 2025-03-13 Acelyrin, Inc. Methods of treating hidradenitis suppurativa

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
US20100004134A1 (en) 2007-01-12 2010-01-07 Lawrence Horowitz Combinatorial libraries of conformationally constrained polypeptide sequences
EP2546261A3 (en) 2007-07-31 2013-08-14 Affibody AB New compositions, methods and use
DK2231860T3 (da) * 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
CA2789738C (en) 2010-03-08 2021-03-09 Ge Healthcare Bio-Sciences Ab Immunoglobulin g fc region binding polypeptide
ES2676403T3 (es) 2010-07-09 2018-07-19 Affibody Ab Polipéptidos
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2597102A1 (en) * 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
HRP20190522T1 (hr) * 2012-02-20 2019-05-03 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi koji se vežu za humani komplement c5
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
US10011641B2 (en) * 2012-10-25 2018-07-03 Affibody Ab ABD binding polypeptide
TW201514310A (zh) * 2013-01-21 2015-04-16 Abbvie Inc 發炎性疾病之抗－ｔｎｆ與抗－ｉｌ１７組合療法生物標記
KR102191654B1 (ko) * 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
US10934335B2 (en) 2021-03-02
MX394167B (es) 2025-03-24
ZA201704366B (en) 2022-09-28
US20250101074A1 (en) 2025-03-27
PT3245224T (pt) 2020-10-08
BR112017014559A2 (pt) 2018-05-15
WO2016113246A1 (en) 2016-07-21
JP2018508186A (ja) 2018-03-29
AU2016208161B2 (en) 2020-01-16
US20210253659A1 (en) 2021-08-19
EP4643955A3 (en) 2026-01-14
RU2017127012A3 (es) 2019-06-24
CA2972683A1 (en) 2016-07-21
EP4643955A2 (en) 2025-11-05
KR20170116023A (ko) 2017-10-18
ES2822431T3 (es) 2021-05-04
IL253004B (en) 2021-06-30
EP3245224A1 (en) 2017-11-22
EP3738976A1 (en) 2020-11-18
NZ732978A (en) 2022-01-28
KR20240110106A (ko) 2024-07-12
US12221464B2 (en) 2025-02-11
PL3245224T3 (pl) 2021-01-25
US20170362290A1 (en) 2017-12-21
CN108064235A (zh) 2018-05-22
MY188784A (en) 2021-12-31
JP7208963B2 (ja) 2023-01-19
EP3738976B1 (en) 2025-07-23
HUE052121T2 (hu) 2021-04-28
EP3245224B1 (en) 2020-07-15
AU2016208161A1 (en) 2017-07-13
JP7456024B2 (ja) 2024-03-26
KR102683288B1 (ko) 2024-07-11
EP3738976C0 (en) 2025-07-23
JP6943764B2 (ja) 2021-10-06
JP2021073174A (ja) 2021-05-13
RU2017127012A (ru) 2019-02-14
RU2749712C2 (ru) 2021-06-16
IL253004A0 (en) 2017-08-31
DK3245224T3 (da) 2020-09-21
JP2023052258A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2017008660A (es) Polipeptidos enlazados a il-17a.
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
MY187827A (en) New polypeptide having affinity to pd-l1
EP3957723A3 (en) Engineered ligase variants
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
BR112018007017A2 (pt) polipeptídeos
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MY198059A (en) Anti-ox40 antibodies and their uses
MX2015016627A (es) Vacuna para la malaria.
MX2015011075A (es) Peptidos terapeuticos.
MX375049B (es) Proteinas especificas novedosas para pioverdina y pioquelina.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
EA201591421A1 (ru) Препараты полипептида фактора ix
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2015002705A1 (es) Anticuerpos anti-cd52.
BR112017009560A2 (pt) preparação de material microporoso compósito baseado quitosana e suas aplicações
MX2020004512A (es) Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.